VpreB2 Inhibitors
VpreB2 inhibitors pertain to a specialized class of chemical agents designed to selectively interact with the VpreB2 protein, which plays a crucial role in the early stages of B cell development. VpreB2, also known as the surrogate light chain, is part of the pre-B cell receptor (pre-BCR) complex and is vital for the proper maturation and function of B lymphocytes. The VpreB2 protein works in tandem with another component called λ5 to form the surrogate light chain, which temporarily associates with the immunoglobulin mu heavy chain on the surface of immature B cells. This interaction is essential for the stabilization of the mu heavy chain and is a key step in the quality control process during B cell maturation. Inhibitors that target VpreB2 are designed to bind with high specificity and affinity to the VpreB2 component, thereby modulating its function. This modulation can influence the signaling pathways that are initiated by the pre-BCR complex.
The development of VpreB2 inhibitors is grounded in the intricate understanding of the molecular biology of B cells and the signaling cascades they initiate. By interacting with the VpreB2 protein, these inhibitors can affect the complex cascade of events that normally occur during B cell development. Since the pre-BCR complex, including VpreB2, plays a critical role in the checkpoint that ensures only functional B cells proceed in development, VpreB2 inhibitors can potentially alter this checkpoint. The exact molecular interactions and the binding kinetics between the inhibitors and the VpreB2 protein are subject to rigorous research and characterization. The design of these inhibitors often involves the use of high-throughput screening techniques, molecular docking, and structure-activity relationship (SAR) studies to optimize their interaction with the target protein. Understanding the biochemical pathways affected by the modulation of VpreB2 activity is crucial for predicting the outcomes of such interactions, which hinge on the precise engagement of these inhibitors with the protein and the subsequent biochemical responses elicited within the B cells.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that targets multiple kinases including the Src family kinases. VpreB2 is part of the pre-B cell receptor complex, and Src family kinases are crucial for initiating signaling from the receptor. Inhibition of these kinases by Dasatinib would lead to reduced phosphorylation and activation of downstream signaling molecules, thereby indirectly inhibiting the functional activity of VpreB2. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a selective inhibitor of certain tyrosine kinases, including ABL. The ABL family of kinases interacts with the pre-B cell receptor signaling pathway, which VpreB2 is a component of. By blocking ABL kinases, Imatinib indirectly decreases the signal transduction and functional activity of VpreB2. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $81.00 | 5 | |
Leflunomide is an immunomodulatory drug that inhibits dihydroorotate dehydrogenase, leading to a decrease in pyrimidine synthesis, which is crucial for lymphocyte proliferation. By limiting lymphocyte proliferation, the expression and assembly of VpreB2 in pre-B cells would be indirectly reduced. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes upstream of ERK in the MAPK pathway. The MAPK pathway is involved in cell proliferation and differentiation, processes that are necessary for B cell development. Inhibition of this pathway by U0126 could indirectly decrease the functional activity of VpreB2 by affecting pre-B cell maturation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which play a significant role in B cell receptor signaling. Inhibition of PI3K activity by Wortmannin would result in impaired B cell receptor-mediated signaling, indirectly affecting the function of VpreB2 in pre-B cells. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that affects cell growth and proliferation. Since mTOR signaling is important for B cell development, Rapamycin can indirectly inhibit the functional activity of VpreB2 by impairing pre-B cell growth and differentiation. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a selective inhibitor of Src family kinases. As Src kinases are involved in early B cell receptor signaling, PP2 would indirectly inhibit VpreB2 activity by reducing the activation of downstream signaling pathways necessary for pre-B cell receptor function. | ||||||
Syk Inhibitor IV, BAY 61-3606 HCl | 732983-37-8 | sc-202351 | 2 mg | $321.00 | 25 | |
BAY 61-3606 is an inhibitor of spleen tyrosine kinase (Syk), which is a key component of the B cell receptor signaling complex. Suppression of Syk activity would impair the signal transduction in which VpreB2 is involved, leading to an indirect inhibition of its function. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor. BTK is essential for B cell receptor signaling. Inhibition of BTK by Ibrutinib will lead to a reduction in signaling events that are necessary for the function of VpreB2, thereby indirectly inhibiting its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a chemical inhibitor of PI3K. By inhibiting PI3K, LY294002 disrupts signaling pathways involved in B cell activation and proliferation, which would indirectly lead to a decrease in the functional activity of VpreB2. | ||||||